Novavax Inc. announced on Monday it has requested the authorization of its COVID-19 booster vaccine in people who have already received other approved shots in the United States. "It's important for people to have a choice as they evaluate how to stay protected against COVID-19," Chief Executive Stanley Erck noted amid the worse-than-expected vaccine rollout across the country.
Novavax's vaccine has been administered 9,700 times in the US, out of 606 million shots given so far to around two-thirds of the Americans that have been fully vaccinated. In its latest earnings report, Novavax halved its 2022 revenue forecast impaired by slow sales of its vaccine in the US.
